SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.131
-0.019 (-1.66%)
Jan 22, 2025, 1:04 PM EST - Market open
SLS Employees
SELLAS Life Sciences Group had 16 employees as of December 31, 2023. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
n/a
Profits / Employee
-$2,017,500
Market Cap
79.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
SLS News
- 14 days ago - SELLAS Announces Key Business Objectives for 2025 - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewsWire
- 6 weeks ago - SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - GlobeNewsWire
- 2 months ago - SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS) - Business Wire
- 2 months ago - SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewsWire
- 3 months ago - SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - GlobeNewsWire